Jason B.Lissy

Partner

New York + 1.212.326.3676

Connect:

Share

Jason Lissy's practice focuses on insurance coverage, exclusively on behalf of policyholders, and other commercial litigation in state and federal courts, arbitrations, and mediations.

Selected by Law360 in 2017 as a "Top Attorney Under 40" in the insurance law category (one of five attorneys nationwide) and recognized by The Legal 500 as a "Next Generation Lawyer" (2018) and "Rising Star" (2019-2021), Jason has advised policyholders in some of the most complex, high-stakes coverage disputes across the country involving catastrophic property loss and business interruption, builder's risk, directors and officers liability, professional liability, employment practices liability, and commercial general liability claims.

Jason is experienced in all stages of litigation and non-adversarial dealings with insurers, including coverage analysis and claims correspondence, pleadings, written discovery, motion practice, trial preparation, and settlement.

Jason is a member of the Risk and Insurance Management Society (RIMS) New York Chapter and the Insurance Law Section of the New Jersey State Bar Association.

Experience

  • MF Global resolves dispute with holdout E&O insurersIn a collaboration among its Business Restructuring & Reorganization, Insurance Recovery and Issues & Appeals practices, Jones Day represented MF Global Holdings Ltd. and its affiliates ("MF Global") in litigation against certain dissenting insurance companies that refused to contribute to a 2016 global settlement of multi-district litigation brought by MF Global’s former commodities futures customers.
  • Celgene resolves False Claims Act case related to alleged off-label promotion of Thalomid® and Revlimid®Jones Day represented Celgene Corporation in a False Claims Act lawsuit related to allegations that Celgene promoted the cancer treatment drugs Thalomid® and Revlimid® for off-label uses prior to their FDA approval for such uses, and paid kickbacks to physicians in order to get them to promote and prescribe those drugs.
    • View All

    June 2023 Commentary

    What's Old Is New Again: Anticipating and Defeating Insurer Coverage "Defenses" for Climate Change Litigation

    October 2022 Commentary

    Maximizing Insurance Recoveries for Hurricane Ian Losses and the Remainder of the 2022 Hurricane Season

    August 2022 Commentary

    Evaluating Directors and Officers Liability Coverage for Emerging ESG-Related Risks

    April 2022 Commentary

    Policyholders Should Not Overlook Traditional Policies in Evaluating Coverage for Cryptocurrency-Related Risks

    March 2022 Alert

    Political Risk Insurance May Cover Business Losses Resulting From Russia's Invasion of Ukraine

    January 2022 Alert

    Newly Enacted Law Ups the Ante on Mandatory Insurance Disclosure Requirements in New York State Court Litigation

    December 2021 Alert

    New York High Court Finds Disgorgement Payment Insured "Loss" Rather Than Uninsurable "Penalty"

    October 2021 Alert

    Federal Court Rejects Application of D&O Policy's "Bump-Up" Exclusion to Merger Litigation

    September 2021 Commentary

    Maximizing Insurance Recoveries for Hurricane Ida Losses and the Remainder of the 2021 Hurricane Season

    January 2021 Alert

    English Supreme Court Confirms Broad Application of Business Interruption Policies to COVID-19 Losses
    View All

    Speaking Engagements

    • February 2022
      Preserving and Maximizing Protection: What You Need to Know About Contractual Indemnities and Insurance Coverage
    • February 2021
      Bad Faith Claims When Verdicts Exceed Policy Limits: Navigating Nuances of the Insurer's Duty to Settle, Strafford Publications Webinar
    • January 2020
      Bad Faith Claims When Verdicts Exceed Policy Limits: Navigating Nuances of the Insurer's Duty to Settle, Strafford Publications Webinar

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.